

Correlation of Magnetic Resonance Spectroscopy with Histopathology of Brain Biopsies

Ali Bashir Ali Elhaj^{2,5}, Mohammed Ahmed Ali Omer^{1,2}, Mogahid M. A Zidan^{4,5}, Wadah M. Ali^{3,4}, Jihad Hamid⁴

¹College of Applied Medical Science-Department of Radiologic Technology- Qassim University, Buraidah, KSA

²Department of Radiotherapy & Nuclear Medicine, College of Medical Radiologic Science, Sudan University of Science and Technology, Khartoum, Sudan

³Medical Imaging Department, College of Allied Medical Science, Gulf Medical University, Ajman, UAE

⁴Nuclear Medicine Department, College of Radiological Science and Nuclear Medicine, The National Ribat University, Khartoum, Sudan

⁵Al-Ghad International College for Applied Medical Science, Medical Imaging Technology Department, Abha, KSA

Abstract: *The pathology of human tissue can be determined by magnetic resonance spectroscopy (MRS) but it was a controversial field for over 20 years. Now MRS on human biopsies identifies disease processes, neoplastic status, and prognostic variables with high accuracy. The MRS databases were compared with careful and specialized histology. The MR method is fast, accurate, and robust and for most organs complements routine histopathological diagnosis. Study was performed to evaluate the rule of Magnetic Resonance Spectroscopy in diagnosis of brain tumors compare by histopathology. A total of 38 patients were examined in this study. The data collected from three hospitals in Khartoum state from 2014 to July 2015. The patients were examined with the own department protocol using Magnetic resonance machine. The study founded that (86.8%) of patients examined by Spectroscopy have same results compare to the histopathology results. Conclusion: MRS is an accurate, noninvasive diagnostic technique for quantifying brain tumors.*

Keywords: Brain-tumors, Spectroscopy, Histopathology, Metabolite

1. Introduction

As stated The incidence of brain tumors (BTs) increases annually by (De Moor, Janet S., et al 2013); [1] There are approximately 2,500 new diagnosed case per year in the USA and the incidence of brain tumors has increased slightly over the recent decades which is possibly ascribed to improved diagnostic imaging technologies (Gill, S. K., Panigrahy et al 2013). [2] Despite the fact that the actual incidence and prevalence worldwide is still remains in accurately measured or detected, with 80% of patients with malignant brain tumors die from the disease.

At present, brain biopsy represents the reference standard for diagnosing brain mass, although the drawbacks of this invasive technique are well known. It is associated with morbidity and mortality, it has sampling errors, and it is not appropriate for screening, longitudinal monitoring, or evaluating treatment response [3]. Among the currently available imaging modalities, magnetic resonance imaging (MRI) and ¹H MR spectroscopy (MRS) are the most reproducible, safe, and accurate imaging techniques that can be used in clinical trials and epidemiologic studies [4]. However, MRS has limited clinical applicability or availability because it requires sophisticated post processing methods, and not every MRI is routinely equipped with MRS capabilities. Recent improvements in MRI can provide the magnetic resonance imaging estimated proton density fat fraction (MRI-PDFF), which is a novel biomarker that has demonstrated robust correlation and equivalency with MRS [5-6].

In addition, MRI-PDFF allows fat mapping of the entire liver, and it can be used with any clinical MRI platform, where as MRS measures fat biochemically in small regions of interest (ROIs). To the best of our knowledge, few studies have used MRS and histology to investigate brain content in patients with BTs [7-8].

2. Materials and Methods

The study was performed in Royal Care hospital in Khartoum State 38 patients (20 males, 18 females; age range, 4–80 years) have been examined using MRI scanner (1.5 tesla-Toshiba Advantage-Japan 2009).

2.1 MRI protocol

All the cases were examined in supine position with standard circularly polarized head coil using the following sequences. Axial and Sagittal T1WI (550/8.7 ms) TR/TE spin echo. Coronal T2WI (5000/96 ms) TR/TE spin echo. Axial FLAIR (9000/92/ms) TR/TE spin echo. 5 mm section thickness, 230-230 Field of view (FOV) and 256-256 matrix size

All of cases which require contrast administration to confirm tumor diagnosis, intravenous administration of Gadolinium- DTPA, contrast enhanced T1WI in axial, sagittal and coronal planes was performed. About 38 cases with confirmed diagnosis MRS were done using single voxel technique.

2.2 MRS protocol

Two localization methods have been performed, each has a different TE. Data were acquired using Point Resolved Spectroscopy (PRESS) pulse sequence and spectroscopic localization has been performed on post contrast T1WI with automatic shimming. All the MR Spectroscopy was performed using single voxel technique initially post contrast imaging was done to localize the tumors and then voxel was placed on volume of interest.

Measurement parameters used in 2D-MRSI were TR/TE: 1500/135 ms, (FOV): 120 _ 120 mm, section thickness: 10 mm and total scan time was 7 min. The Region of interest (ROI) was carefully placed to avoid strong interference from subcutaneous fat and lipids of the skull, and outer volume

suppression (OVS) slabs outside the ROI was used to further reduce the potential for artifact. Measurement parameters used in SVS scans were 1500/35 ms (TR/TE) and voxel size was about 1.5 cm³. The total Scan time was 3.14 min. 1.2.

Analysis of the spectroscopic data: The main metabolites identified by MRS are (NAA) at 2.02 ppm, (Cr) at 3.0 ppm and (Cho) at 3.2 ppm. Concerning lipids and lactate (LL) were qualitatively defined and estimated their sum between 0.9 and 1.3 parts per mil (ppm). The following metabolite ratio was calculated using the standard commercial software. A spectrum was excluded for analysis if integration of any peak could not be accomplished using the automated analysis software.

36700- 70300 + 8400

Metabolite	Major resonance (ppm)	Physiological significant	Increase	Decrease
NAA	2.0	Marker of neuronal health. See only in neuronal tissues	Rarely in canavan disease	Neural damage
Cho	3.2	Marker of membrane synthesis and NO of cells	Active tumors growth	HIV & Liver disease
Cr	3.0	Energy metabolism. stable in many disease	Trauma	Tumors & hypoxia
Lipids (Lip)	0.8 - 1.4	Normally not present or very low	Necrotic tumors ,stroke and abscess	-
Lactate (Lac)	1.3	Normally not present or very low	Necrotic tumors ,stroke and abscess	-
Glutamate & Glutamine (Glx)	2.1 - 2.6	Regulation of neurotransmitter activity	Hepatic encephalopathy& severe hypoxia	-
Myo-inositol (MI)	3.5	Used as astrocytes marker	Glioma, Alzheimer and gliomatosis	Hepatic encephalopathy

MRS (single or multi-voxel technique) is noninvasive diagnostic procedure for brain metabolite that could register the pattern of tissue with chemical compounds (Choline compounds (Cho), Creatine and Phosphocreatine (Cr), N-Acetyl-Aspartate (NAA), and Lactate (Lac)) and map out the spatial distribution of metabolites within the brain.

The diagnostic findings of MRS depend on the following: (High Choline indicate brain malignancy, weak NAA signal refers to replacement of healthy brain tissue by tumor cells, level of Cr refers to high energy metabolism and Lac refers to anaerobic metabolism).

3. Results




Figure 1: Shows the gender distribution in this study.

Table 1: Demonstrate the correlation of histopathology with Magnetic Resonance Spectroscopy of human biopsies

No	MRS Result	Histopathology Result	
1.	Malignant	Malignant	
2.	Malignant	Malignant	
3.	Malignant	Malignant	
4.	Malignant	Malignant	
5.	Benign	Benign	
6.	Malignant	Malignant	
7.	Malignant	Malignant	
8.	Cystic	Benign	*
9.	Malignant	Malignant	
10.	Malignant	Malignant	
11.	Malignant	Malignant	
12.	Benign	Benign	
13.	Neoplastic tumor	Necrotic tumor	*
14.	Malignant	Malignant	
15.	Abscess	Abscess	
16.	Benign	Malignant	*
17.	Malignant	Malignant	
18.	Malignant	Malignant	
19.	Malignant	Malignant	
20.	Malignant	Benign	*
21.	Malignant	Malignant	
22.	Benign	Benign	
23.	Malignant	Malignant	
24.	Malignant	Malignant	
25.	Benign	Benign	
26.	Benign	Benign	
27.	Benign	Benign	
28.	Benign	Benign	
29.	Malignant	Malignant	

30.	Malignant	Malignant	
31.	Malignant	Malignant	
32.	Malignant	Malignant	
33.	Inflammation	Inflammatory	
34.	Malignant	Malignant	
35.	Malignant	Malignant	
36.	Malignant	Benign	*
37.	Malignant	Malignant	
38.	Benign	Benign	

Note (*) in table referred to deference between the MRS results and histopathology results.




Figure 2 shows the percentage of results matching between the MRS and Histopathology results.

The basis of the MRS method for identifying tumor pathology is the increase in MR visible chemical species with the onset and the development of the disease. Cancer of the uterine cervix was chosen for the first clinical 1H MRS study as, histologically, the distinction between the presence and the absence of malignancy is made with a high level of accuracy.

Our study include 38 brain tumor patients who referred for magnetic spectroscopy MRS at Radiology department at Royal Care hospital (RCH), Radiation and Isotopes Center of Khartoum (RICK) and Alshaab Hospitals in Sudan during 2014-2017.

Out of the patients, 53 % (20) patients were males and 47 % (18) patients were female (figure 1).

The diagnostic study of BTs in Khartoum state using MRS showed little variation in view of accuracy relative to histological findings and our results similar to the Gold standard result; as in Fig. (2); in which MRS showed excellent diagnostic achievement relative to standard (histology) with accuracy 86.8%.

4. Conclusion

The magnetic resonance spectroscopy has a role for evaluating patients with brain tumors by interpretations the MR spectroscopy findings for the specific diagnosis. The study showed that male patients are more than female patients, the most common brain pathologies diagnosed by MR spectroscopy is malignancy followed by benign.

Our results suggest that MRS is an accurate, noninvasive diagnostic technique for quantifying brain tumors.

References

- [1] De Moor, J. S., Mariotto, A. B., Parry, C., Alfano, C. M., Padgett, L., Kent, E. E., ... & Rowland, J. H. (2013). Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. *Cancer Epidemiology and Prevention Biomarkers*, 22(4), 561-570.
- [2] Gill, S. K., Panigrahy, A., Arvanitis, T. N., & Peet, A. C. (2013). Magnetic resonance spectroscopy of pediatric brain tumors. In *MR Spectroscopy of Pediatric Brain Disorders* (pp. 45-60). Springer New York.
- [3] Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. *Hepatology* 2009; 50: 1282-1293 [PMID: 19637286 DOI: 10.1002/hep.23119]
- [4] Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. *Arterioscler Thromb Vasc Biol* 2008; 28: 27-38 [PMID: 17690317 DOI: 10.1161/ATVBAHA.107.147538]
- [5] Nouredin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le TA, Bettencourt R, Changchien C, Brenner DA, Sirlin C, Loomba R. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. *Hepatology* 2013; 58: 1930-1940 [PMID: 23696515 DOI: 10.1002/hep.26455]
- [6] Hines CD, Frydrychowicz A, Hamilton G, Tudorascu DL, Vigen KK, Yu H, McKenzie CA, Sirlin CB, Brittain JH, Reeder SB. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. *J Magn Reson Imaging* 2011; 33: 873-881 [PMID: 21448952 DOI: 10.1002/jmri.22514]
- [7] Hamilton G, Yokoo T, Bydder M, Cruite I, Schroeder ME, Sirlin CB, Middleton MS. In vivo characterization of the liver fat ¹H MR spectrum. *NMR Biomed* 2011; 24: 784-790 [PMID: 21834002 DOI: 10.1002/nbm.1622]
- [8] Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. *Radiology* 2013; 267: 422-431 [PMID: 23382291 DOI: 10.1148/radiol.12120896].